Biotech company I-Mab (IMAB) revealed that it has bagged permission from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration to conduct a phase 2 trial of ...

Under the terms of the partnership, I-Mab will leverage WuXi Bio's expertise and capabilities for CMC development of at least five programs and commercial manufacturing of at least one program for ...